Southampton, UK – 13 December 2005 – Karus Therapeutics is pleased to announce it has entered into a collaborative agreement with AIM-listed Sareum Holdings plc, a specialist structure-based drug discovery and services business. Sareum will provide computational chemistry expertise to support Karus’s therapeutic discovery programmes based on inhibitors of histone deacetylase (HDAC). Financial terms of the agreement were not disclosed.
Commenting on the announcement, Karus’s Founder Director, Dr A Ganesan said: “We are excited at the opportunity to work with Sareum. In a short period of time they have established a reputation as a high-quality provider of research tools for drug discovery. We believe their expertise and resources will have a significant impact upon our programme.”
Commenting on the agreement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said: “We are delighted that we have been chosen by Karus to provide these drug discovery services and we look forward to making a valuable contribution to their development programmes.”